Short answer
STAAR SURGICAL CO (STAA) filed an 8-K current report with the SEC on April 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Preliminary first-quarter results for period ended April 3, 2026, disclosed under Regulation FD.
STAAR SURGICAL CO 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Preliminary first-quarter results for period ended April 3, 2026, disclosed under Regulation FD
- Full Q1 financial results expected in early May 2026
- Exhibit 99.1 contains the selected preliminary financial results and primary investor detail
Item EX-99.1 · Exhibit EX-99.1
- Preliminary Q1 2026 net sales expected above $90 million versus $42.6 million in Q1 2025
- China drove most sales growth as EVO ICL distributor inventory returned to the targeted range
- Continued double-digit growth in the Americas, supporting broader demand momentum
- Higher sales and improved cost structure expected to produce meaningful adjusted EBITDA improvement
- Geopolitical and macroeconomic pressures reduced sales in parts of EMEA and APAC; no forward guidance provided
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STAAR SURGICAL CO 8-K filings
Get the next STAA 8-K as it lands
Follow STAA for push alerts, or ask the research agent what this filing means.